



Clinical trial results: Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR)

Summary

EudraCT number	2015-003723-65
Trial protocol	GB
Global end of trial date	20 November 2018

Results information

Result version number	v1 (current)
This version publication date	20 June 2019
First version publication date	20 June 2019
Summary attachment (see zip file)	Final study report (AMOUR FINAL STUDY REPORT 30th May 2018.pdf)

Trial information

Trial identification

Sponsor protocol code	MICM1014
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02661711
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Moorfields Eye Hospital
Sponsor organisation address	162 City Road, London, United Kingdom, EC1V 2PD
Public contact	Gisela Barreto, Moorfields Eye Hospital, +44 02072533411, gisela.barreto@moorfields.nhs.uk
Scientific contact	Gisela Barreto, Moorfields Eye Hospital, +44 02072533411, gisela.barreto@moorfields.nhs.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 November 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 November 2018
Global end of trial reached?	Yes
Global end of trial date	20 November 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To report mean Central Macular Thickness (CMT) at 6 and 12 months as measured with SDOCT in eyes of patients with Retinitis Pigmentosa associated with cystoid macular oedema treated with three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between baseline and twelve months.

Protection of trial subjects:

Non-study eye was treated in accordance with NHS standards of care and was monitored throughout the study.

Background therapy:

Patients stopped topical and/or oral treatment for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) in the study eye whilst undertaking this study. Topical treatment in the non-study eye could be continued throughout the study if the patient wished to continue this.

Evidence for comparator:

The study drug was not compared to another drug during this trial

Actual start date of recruitment	14 March 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 30
Worldwide total number of subjects	30
EEA total number of subjects	30

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	30

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Patients will be recruited over a 6 to 12 month period. Within a week of being approached in the medical retina clinics or by telephone and having been provided with information about the trial, our research manager will contact the patient and invite them to attend a screening appointment.

Pre-assignment

Screening details:

130 patients were found to be suitable participants. 18 could not be contacted, 1 was deceased, 32 wished to be considered for the study, and 79 others declined for various reasons.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not blinded

Arms

Arm title	Intravitreal aflibercept for RP-CMO
------------------	-------------------------------------

Arm description:

Intravitreal aflibercept for RP-CMO

Arm type	Experimental
Investigational medicinal product name	Aflibercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for suspension for injection
Routes of administration	Intravitreal use

Dosage and administration details:

Eylea solution is supplied in a vial (40mg/ml). Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. This provides a usable amount to deliver a single dose of 50 microlitres containing 2 mg aflibercept. The dose used in this trial will be 0.05ml (2mg) per intravitreal injection.

Number of subjects in period 1	Intravitreal aflibercept for RP-CMO
Started	30
Completed	29
Not completed	1
Did not wish to continue in the study	1

Baseline characteristics

Reporting groups

Reporting group title	Overall trial
Reporting group description: -	

Reporting group values	Overall trial	Total	
Number of subjects	30	30	
Age categorical			
All patients in the trial were aged between 18 -64 years			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	30	30	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	13	13	
Male	17	17	

Subject analysis sets

Subject analysis set title	Overall cohort
Subject analysis set type	Full analysis
Subject analysis set description: The overall cohort	
Subject analysis set title	Responders
Subject analysis set type	Sub-group analysis
Subject analysis set description: Patients who were deemed as 'responders'	

Reporting group values	Overall cohort	Responders	
Number of subjects	30	11	
Age categorical			
All patients in the trial were aged between 18 -64 years			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	

Adolescents (12-17 years)	0	0	
Adults (18-64 years)	30	11	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	13	3	
Male	17	8	

End points

End points reporting groups

Reporting group title	Intravitreal aflibercept for RP-CMO
Reporting group description: Intravitreal aflibercept for RP-CMO	
Subject analysis set title	Overall cohort
Subject analysis set type	Full analysis
Subject analysis set description: The overall cohort	
Subject analysis set title	Responders
Subject analysis set type	Sub-group analysis
Subject analysis set description: Patients who were deemed as 'responders'	

Primary: Mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline

End point title	Mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline ^[1]
End point description: To report the efficacy of aflibercept in RP-CME via mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline.	
End point type	Primary
End point timeframe: 12 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were used for this study

End point values	Overall cohort	Responders		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed				
Units: Microns	413	350		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

12 months

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	Bayer plc., 2015
-----------------	------------------

Dictionary version	1
--------------------	---

Reporting groups

Reporting group title	Serious adverse event
-----------------------	-----------------------

Reporting group description: -

Serious adverse events	Serious adverse event		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 30 (3.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Eye disorders			
Sub-acute reduction of vision	Additional description: Reduction in vision most likely secondary to progression of underlying retinitis pigmentosa rather than as a consequence of ivA		
subjects affected / exposed	1 / 30 (3.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0.05 %

Non-serious adverse events	Serious adverse event		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 30 (83.33%)		
Eye disorders			
Ocular adverse events	Additional description: These included: floater, sub-conjunctival haemorrhage, blurring of vision, corneal epithelial defect, dry cornea, chalazion, grittiness, raised intra-ocular pressure, corneal abrasion and soreness.		
subjects affected / exposed	25 / 30 (83.33%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 December 2015	We requested to analyse data at 6 months as well as at 12 months

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

N/A

Notes: